11/5/2026

speaker
Conference Operator
Operator

Welcome everyone to the third quarter 2026 Regenexx BIO earnings conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. I will now turn the conference over to Patrick Christmas, Chief Legal Officer of RegenXBIO. Please go ahead.

speaker
Patrick Christmas
Chief Legal Officer, RegenXBIO

Good morning, and thank you for joining us today. Earlier this morning, RegenXBIO released financial and operating results for the third quarter ended September 30, 2026. The press release is available on our website at www.regenxbio.com. Today's conference call will include forward-looking statements regarding our financial outlook in addition to regulatory and product development plans. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted and can be identified by words such as expect, plan, will, may, anticipate, believe, should, intend, and other words of similar meaning. Any such forward-looking statements are not guarantees of future performance and involve certain risks and uncertainties. These risks are described in the Risks Factors, and the Management's Discussion and Analysis section of GENXBIO's annual report on Form 10-K for the full year ended December 31, 2025, and comparable risk factor sections of GENXBIO's quarterly report on Form 10-Q, which will be on file with the Securities and Exchange Commission and available on the SEC's website. Any information we provide on this conference call is provided only as of the date of this call, November 5, 2026. and we undertake no obligation to update any forward-looking statements we may make on this call on account of new information, future events or otherwise. Please be advised that today's call is being recorded in webcast. In addition, any unaudited or pro forma financial information that may be provided is preliminary and does not purport to project financial positions or operating results of the company. Actual results may differ materially. I'll now turn the call to Curran Simpson, President and CEO of Regenexx Bio.

speaker
Curran Simpson
President and Chief Executive Officer, RegenXBIO

Thank you, Patrick, and good morning, everyone. Thank you for joining us today. This is an exciting time for RegenXBIO. We are on the cusp of multiple potential regulatory approvals and are preparing for commercialization. Joining me today are Dr. Steve Pakola, our Chief Medical Officer, and Mitch Chan, our Chief Financial Officer. I'll provide an update on our lead programs before turning it over to them for additional details. I'll begin with SuraVec, our potential first-in-class gene therapy for wet AMD and diabetic retinopathy, developed in collaboration with AbbVie. Ahead of our top-line pivotal readout expected later this year, last month we hosted an investor event featuring five leading retina specialists. They discussed the opportunity for SuraVec to transform the wet AMD treatment paradigm. I want to highlight Three key takeaways from the event. First, the unmet need in wet AMD remains significant. While anti-VEGF therapies are highly effective, the burden of frequent injections can be difficult for patients to sustain over time. As a result, patients who are unable to maintain consistent treatment schedules may not realize the full potential benefit of today's standard of care and subsequently lose vision. Second, Cerevec has the potential to benefit a broad spectrum of patients, including those with high disease activity and those with bilateral disease. During our event, the physicians reinforced the advantages of a one-time treatment across the range of wet AMD patients they treat and pointed to patients with high disease burden as ideal candidates for gene therapy. We and AbbVie incorporated these patients in our clinical studies, giving us a potential advantage in obtaining a broad label and treating these patients commercially. Cirovec pivotal studies include a broad population of patients, including newly diagnosed and treatment-experienced patients. Additionally, Cirovec is the only late-stage gene therapy program with reported clinical data supporting treatment in both eyes. Third, Cirovec is well positioned for commercial adoption. The commercial infrastructure for subretinal delivery already exists due to Luxturna and other approved therapies. Further, we know the majority of retina specialists performing these procedures are at high volume centers, many of whom are included in our pivotal studies. We at AbbVie have already laid a significant foundation having trained over 500 retina specialists to date. Together, these factors, combined with AbbVie's global reach and leading eye care capabilities, give us confidence as we proceed towards potential commercial launch. We expect top line results from both Atmosphere and Ascent this quarter, followed by global regulatory submissions in 2027. Looking ahead, we see wet AMD as the tip of the spear in terms of transforming the treatment paradigm for chronic retinal diseases. We are currently enrolling in the Phase 2b-3 Navigate Study in Diabetic Retinopathy. Current anti-VEGF therapy is vastly underused in DR due to the treatment burden for patients who are predominantly middle-aged working adults. We believe a one-time gene therapy has the potential to address this large unmet need and represents another potential blockbuster opportunity for Serovac. Turning to RGX202, we continue to make meaningful progress towards bringing our potential best-in-class gene therapy for Duchenne to patients in the U.S. and beyond. Preparations are well underway to submit the BLA under the accelerated approval pathway in the first quarter of 2027, supporting potential approval in the U.S. in the second half of 2027. As a reminder, the BLA is expected to include data from both our pivotal and confirmatory studies. Outside of the U.S., momentum for RGX202 continues and we remain on track to initiate our XUS randomized placebo-controlled study named AffinityRISE in the first half of 2027. We continue to be highly encouraged by the impressive microdystrophin functional and safety data to date, which demonstrate the potential of RGX202 to meaningfully improve outcomes for patients with Duchenne. We have strong support from treating physicians families, and advocacy organizations. At our FDA-inspected in-house manufacturing innovation center, we continue to manufacture intended commercial supply in anticipation of a potential 2027 commercial launch. We are sharply focused on advancing our late-stage pipeline, executing against upcoming milestones and making disciplined investment decisions that support these priorities. With that, I'll turn it over to Steve.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API